HedgePath Pharmaceuticals to Present at the 2018 BioFlorida Annual Conference


BIOBUSINESS: Spotlight on Innovation
Monday, October 15, 2018 at the Westin Fort Lauderdale, Florida


TAMPA, Fla., Oct. 11, 2018 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize therapeutics for patients with cancer, announced today that Nicholas J. Virca will participate on a panel with three other biopharmaceutical Florida-based companies chosen to be highlighted in the BIOBUSINESS: Spotlight on Innovation Session at the Westin Fort Lauderdale, during the 2018 BioFlorida Annual Conference.

HedgePath Pharmaceuticals, Inc. (PRNewsFoto/HedgePath Pharmaceuticals, Inc.)

Mr. Virca will also present an overview of HPPI's technology for inhibition of the Hedgehog Pathway, its 505(b)(2) regulatory strategy for repurposing an already FDA-approved drug with an orphan designation, and key milestone achievements regarding the Company's clinical development program for SUBA™-Itraconazole as a treatment for Basal Cell Carcinoma (BCC) in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome, including its progress toward filing a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in early 2019 for treatment of BCC in BCCNS patients.

Following the Spotlight on Innovation Session, HPPI will post Mr. Virca's presentation on its website at www.hedgepathpharma.com.

About SUBA-Itraconazole

HPPI's lead drug candidate, SUBA-Itraconazole, is a patent-protected formulation of itraconazole, an approved oral antifungal drug that has been in use for over 25 years.  HPPI is the exclusive U.S. licensee (through Mayne Pharma, the majority stockholder of HPPI) of SUBA-Itraconazole for the treatment of cancer.  Prior to research at Johns Hopkins University, itraconazole was not known to have any target in mammalian cells. Investigators at Johns Hopkins discovered that itraconazole inhibits the hedgehog pathway by binding to a surface receptor in the pathway called Smoothened.  Unlike generic itraconazole, that has poor and unpredictable bioavailability, SUBA-Itraconazole can be dosed at half the level of the generic formulation due to its superior bioavailability, which exceeds 90%.  As such, HPPI believes that generic itraconazole cannot be substituted for SUBA-Itraconazole.


HPPI's initial indication is for the orphan disease BCCNS. SUBA-Itraconazole has qualified under the FDA's Orphan Drug Designation Program as a potential therapy for BCCNS.  There is no approved pharmaceutical therapy for this familial cancer syndrome.  There are estimated to be 10,000 patients in the U.S. with BCCNS.  This is an autosomal dominantly inherited defect in the hedgehog pathway that causes the pathway to be up-regulated, resulting in hundreds or even thousands of basal cell carcinomas developing over the lifetime of the affected patients.  In many types of cancers, the hedgehog pathway is basically hijacked by the cancer cells to assist their growth and metastatic spread, but in the case of basal cell carcinomas, whether in this hereditary syndrome or in the much more common, sporadic basal cell carcinomas, the hedgehog pathway has a mutation that makes it the sole driver of the development of BCC tumors.  Inhibition of the pathway, then, can inhibit the appearance of new tumors, shrink existing tumors, and even cause some tumors to disappear altogether.

Cautionary Note Regarding Forward Looking Statements

This press release and any statements of representatives and partners of HedgePath Pharmaceuticals, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the actual timing for, or actual results of, the Company's clinical trial described herein, the Company's meeting with FDA or the FDA's review of any trial data or New Drug Application submitted by the Company to FDA as described herein) may differ significantly from those set forth or implied in the forward-looking statements (and may further differ from the interim study results previously disclosed by the Company).  These forward-looking statements involve numerous risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

For more information:

Nicholas J. Virca, President and CEO

Investor Relations Contact:
Garrison Hasara, CFO and Treasurer

© 2018 HedgePath Pharmaceuticals, Inc.  All rights reserved.



Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hedgepath-pharmaceuticals-to-present-at-the-2018-bioflorida-annual-conference-300729568.html

SOURCE HedgePath Pharmaceuticals, Inc.


Back to news